Barclays has cut its price target for Collegium Pharmaceutical to $41, down from $48.

Nov 13, 2026, 5:44 PM ETOpinionRead the original at marketscreener.com

Neutral

Barclays lowered its share-price target but kept its Overweight rating. These mixed views concern the shares, not a reported change in Collegium's business.

COLL · Collegium Pharmaceutical, Inc.

AI read · Neutral

The AI's read

This changes Barclays' view of the shares, not any reported company results. The lower target points one way, but keeping the Overweight rating points the other. The report gives no clear reason to change the company's business outlook.

Get alerts for COLL

Follow Collegium Pharmaceutical, Inc. (COLL) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for COLL

Free on the App Store and Google Play, or on the web.